With regard to preclinical findings of TrkB as a viable target in lung cancer, a recent study showed that in lung adenocarcinoma models driven by KRAS and p53 loss, increased TrkB expression was correlated with more aggressive lung cancer tumors, and that TrkB was required for lung tumor metastases in vivo. Here, TP53 is linked to lung adenocarcinoma.